Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: C 105; L-alpha-methylphenethylamine; L-amfetamine; L-amfetamine sulfate; L-amphetamine; L-amphetamine sulfate; Levamfetamine; Levoamphetamine

Latest Information Update: 26 Sep 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Brown University; Sention
  • Developer Cognition Pharmaceuticals
  • Class Amphetamines; Antidementias; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Neurotransmitter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cognition disorders

Most Recent Events

  • 19 Dec 2008 Interim efficacy and safety data from the phase II, NCT00529581 trial in patients with cognitive impairment due to multiple sclerosis (Cognition disorders) released by Cognition Pharmaceuticals
  • 30 Apr 2008 Cognition Pharmaceuticals completes the phase II, NCT00529581 trial for cognitive impairment in patients with multiple sclerosis (Cognitive disorders) in USA
  • 19 Jan 2005 Sention completes phase I trials in Cognitive disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top